Polyrizon (PLRZ) previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.

has started preclinical studies for an intranasal formulation of Naloxone, intended to treat opioid overdoses. Collaborating with Professor Fabio Sonvico from the University of Parma, the studies ...

Thirty thousand fewer people are dying every year in the U.S. from fentanyl and other street drugs. This shift has stunned ...

The vehicle rolled up to the ambulance entrance at NorthBay Medical Center, and the frantic driver rushed to get medical help ...

These preclinical studies mark a step forward in evaluating Polyrizon's Trap and Target™ (T&T) platform for the intranasal administration of Naloxone, an opioid antagonist designed to rapidly ...

What you need to know about opioid overdose reversal drug nalmefene’s risks, effectiveness and clinical concerns ...

Employees at Smitten Kitten found a woman unresponsive in her car after an overdose. After the owner of the business ...

Health Canada approves Hikma Pharma’s Kloxxado nasal spray 8 mg for treatment of known or suspected opioid overdose: London Monday, March 24, 2025, 13:00 Hrs [IST] Hikma Pharmac ...

March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously ...